Kayne Anderson Rudnick Investment Management’s Anika Therapeutics ANIK Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10	Closed	-$296	–	786
2022 Q4	$296	Sell	10 -2	-17%	-$57	﹤0.01%	670
2022 Q3	$0	Sell	12 -108,938	-100%	-$2.51M	﹤0.01%	643
2022 Q2	$2.43M	Sell	108,950 -1,303,309	-92%	-$29.1M	0.01%	310
2022 Q1	$35.5M	Sell	1,412,259 -54,504	-4%	-$1.66M	0.09%	157
2021 Q4	$52.6M	Buy	1,466,763 +11,170	+0.8%	+$447K	0.12%	148
2021 Q3	$62M	Buy	1,455,593 +6,151	+0.4%	+$253K	0.15%	134
2021 Q2	$62.7M	Buy	1,449,442 +228,201	+19%	+$9.72M	0.15%	133
2021 Q1	$49.8M	Sell	1,221,241 -325,019	-21%	-$12.3M	0.13%	141
2020 Q4	$70M	Buy	1,546,260 +54,650	+4%	+$2.07M	0.2%	117
2020 Q3	$52.8M	Buy	1,491,610 +93,827	+7%	+$3.39M	0.19%	114
2020 Q2	$52.1M	Buy	1,397,783 +70,386	+5%	+$2.32M	0.22%	103
2020 Q1	$38.4M	Sell	1,327,397 -7,082	-0.5%	-$286K	0.22%	97
2019 Q4	$69.2M	Sell	1,334,479 -9,711	-0.7%	-$564K	0.33%	83
2019 Q3	$73.8M	Sell	1,344,190 -283,444	-17%	-$14.6M	0.38%	70
2019 Q2	$66.1M	Buy	1,627,634 +34,313	+2%	+$1.25M	0.35%	73
2019 Q1	$48.2M	Buy	1,593,321 +174,716	+12%	+$5.98M	0.28%	86
2018 Q4	$47.7M	Sell	1,418,605 -129,911	-8%	-$4.69M	0.33%	78
2018 Q3	$65.3M	Sell	1,548,516 -51,657	-3%	-$2.04M	0.38%	69
2018 Q2	$51.2M	Sell	1,600,173 -107,152	-6%	-$4.41M	0.33%	83
2018 Q1	$84.9M	Buy	1,707,325 +40,115	+2%	+$2.27M	0.64%	43
2017 Q4	$89.9M	Buy	1,667,210 +10,292	+0.6%	+$570K	0.73%	38
2017 Q3	$96.1M	Buy	1,656,918 +233,325	+16%	+$12.2M	0.87%	34
2017 Q2	$70.2M	Buy	1,423,593 +88,418	+7%	+$4.07M	0.7%	42
2017 Q1	$58M	Buy	1,335,175 +700,234	+110%	+$33.4M	0.63%	44
2016 Q4	$31.1M	Buy	634,941 +345,675	+120%	+$16M	0.37%	80
2016 Q3	$13.8M	Sell	289,266 -10,981	-4%	-$542K	0.17%	157
2016 Q2	$16.1M	Buy	300,247 +14,097	+5%	+$664K	0.24%	118
2016 Q1	$12.8M	Sell	286,150 -47,388	-14%	-$1.92M	0.21%	132
2015 Q4	$12.7M	Sell	333,538 -7,453	-2%	-$285K	0.21%	128
2015 Q3	$10.9M	Buy	+340,991	New	+$11.9M	0.18%	133

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ANIK Position: Q1 2023 in Review

Kayne Anderson Rudnick Investment Management sold out of Anika Therapeutics (ANIK) in Q1 2023, closing a stake of 10 shares — an estimated $296 sold.

Kayne Anderson Rudnick Investment Management first reported a position in ANIK in Q3 2015 and held it in 30 quarters. The position peaked at $96.1M in Q3 2017. 119 funds tracked by Wall St. Rank hold ANIK as of Q1 2023.

Kayne Anderson Rudnick Investment Management reported no remaining Anika Therapeutics position as of Q1 2023 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 10 Anika Therapeutics shares in Q1 2023, an estimated $296.
Kayne Anderson Rudnick Investment Management first reported a position in Anika Therapeutics in Q3 2015 and held it in 30 quarters.
Kayne Anderson Rudnick Investment Management's Anika Therapeutics position peaked at $96.1M in Q3 2017.
119 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2023.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2023, filed 16 May 2023.